Guggenheim Raises Eli Lilly Price Target on Tirzepatide Success

Guggenheim analysts have raised Eli Lilly's stock price target, citing the strong performance of tirzepatide, a drug used for diabetes and weight loss treatment. The decision reflects the drug's market success and future potential. Analysts note that tirzepatide's efficacy in treating both type 2 diabetes and obesity will significantly contribute to Eli Lilly's revenues. Increasing demand, particularly in the weight loss segment, could further boost sales. Guggenheim's revised target price suggests higher upside potential compared to Eli Lilly's current market valuation, creating a positive sentiment among investors regarding the company's growth prospects. Tirzepatide stands out as a dual-action drug targeting GLP-1 and GIP receptors. This mechanism improves blood sugar control while also supporting weight loss. Eli Lilly continues to invest in R&D to maintain its competitive edge in this area. This is not investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 60%

The news reflects a positive development regarding Eli Lilly's key product, tirzepatide, which is a supportive factor for the stock. However, technical indicators paint a weak picture: the RSI is near oversold territory at 38, the MACD is below the signal line, and the price is below both the 20-day and 50-day moving averages. The 3.75% decline over the past 24 hours indicates continued short-term selling pressure. The positive impact of the news may not fully offset the technical weakness, so upside movement could remain limited.

RSI 14

38.3

MACD

-7.75

24h Δ

-3.75%

Canlı Grafikler